YAP1 and cancer: To fully exploit integrin inhibitors to treat YAP/TAZ-driven cancer, we must determine which integrins activate YAP and TAZ in a given cancer type, and we must then determine if that integrin-mediated YAP/TAZ activity influences cancer development or metastasis.